454 related articles for article (PubMed ID: 23455378)
1. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
Masui K; Gini B; Wykosky J; Zanca C; Mischel PS; Furnari FB; Cavenee WK
Carcinogenesis; 2013 Apr; 34(4):725-38. PubMed ID: 23455378
[TBL] [Abstract][Full Text] [Related]
2. Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.
Wu S; Singh RK
Curr Mol Med; 2011 Oct; 11(7):553-63. PubMed ID: 21707515
[TBL] [Abstract][Full Text] [Related]
3. Highlights in Resistance Mechanism Pathways for Combination Therapy.
Delou JMA; Souza ASO; Souza LCM; Borges HL
Cells; 2019 Aug; 8(9):. PubMed ID: 31480389
[TBL] [Abstract][Full Text] [Related]
4. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
Berns K; Bernards R
Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
Bagnyukova TV; Serebriiskii IG; Zhou Y; Hopper-Borge EA; Golemis EA; Astsaturov I
Cancer Biol Ther; 2010 Nov; 10(9):839-53. PubMed ID: 20935499
[TBL] [Abstract][Full Text] [Related]
6. Combining targeted drugs to stop resistant tumors.
Kaiser J
Science; 2011 Mar; 331(6024):1542-5. PubMed ID: 21436437
[No Abstract] [Full Text] [Related]
7. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeted therapy for anticancer treatment.
Min HY; Lee HY
Exp Mol Med; 2022 Oct; 54(10):1670-1694. PubMed ID: 36224343
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
Izar B; Rotow J; Gainor J; Clark J; Chabner B
Pharmacol Rev; 2013; 65(4):1351-95. PubMed ID: 24092887
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine in oncology: a personal view with myths and facts.
Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):141-7. PubMed ID: 20406176
[TBL] [Abstract][Full Text] [Related]
11. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
12. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
Austreid E; Lonning PE; Eikesdal HP
Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors: A new era of targeted therapy.
Tangutoori S; Baldwin P; Sridhar S
Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
[TBL] [Abstract][Full Text] [Related]
14. At the crossroads of cancer stem cells and targeted therapy resistance.
Wang A; Qu L; Wang L
Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488
[TBL] [Abstract][Full Text] [Related]
15. Targeted agents: the rules of combination.
Kwak EL; Clark JW; Chabner B
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Drug Combinations, How Far We can Go Through?
Lu DY; Chen EH; Wu HY; Lu TR; Xu B; Ding J
Anticancer Agents Med Chem; 2017; 17(1):21-28. PubMed ID: 27039923
[TBL] [Abstract][Full Text] [Related]
17. [Novel Mechanisms of Resistance to Investigational Molecularly Targeted Drugs].
Noguchi K
Yakugaku Zasshi; 2017; 137(2):151-160. PubMed ID: 28154324
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance to targeted therapies: déjà vu all over again.
Groenendijk FH; Bernards R
Mol Oncol; 2014 Sep; 8(6):1067-83. PubMed ID: 24910388
[TBL] [Abstract][Full Text] [Related]
19. Rational combinations of targeted cancer therapies: background, advances and challenges.
Jin H; Wang L; Bernards R
Nat Rev Drug Discov; 2023 Mar; 22(3):213-234. PubMed ID: 36509911
[TBL] [Abstract][Full Text] [Related]
20. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
